SCHEMBL5714535

SCHEMBL5714535

O=C(O)Cc1ccc(N2CCN(C(=O)Oc3ccc4cccnc4c3)CC2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.42
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TRPA1 O75762 6/20 0.41
CYP3A4 P08684 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
PANK3 Q9H999 1/20 0.41
KMT2A Q03164 2/20 0.40
ME2 P23368 1/20 0.40
ME1 P48163 1/20 0.40
ME3 Q16798 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714980 0.85 KMT2A (0.47) HSD17B10TRPA1CYP3A4ALDH1A1MAPK1
SCHEMBL5714539 0.84 TRPA1 (0.53) HSD17B10TRPA1ALDH1A1SMN1; SMN2TSHR
SCHEMBL5714464 0.84 PANK3 (0.46) TRPA1PANK3KMT2AMEN1POLB
SCHEMBL5715175 0.84 CHRM1 (0.49) TRPA1ALDH1A1PANK3KMT2AMEN1
SCHEMBL5714487 0.83 KMT2A (0.58) HSD17B10HPGDNPSR1L3MBTL1CYP3A4
SCHEMBL5714858 0.82 HTT (0.59) HSD17B10HPGDL3MBTL1TRPA1ALDH1A1
SCHEMBL5689887 0.80 EPHX2 (0.48) CYP3A4ALDH1A1
SCHEMBL5714105 0.80 HSD17B10 (0.48) HSD17B10HPGDNPSR1L3MBTL1TRPA1
SCHEMBL5714523 0.80 SMO (0.47) HSD17B10HPGDNPSR1L3MBTL1TRPA1
SCHEMBL5687989 0.79 MGLL (0.44) CYP3A4ALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HSD17B10 285/4885HPGD 793/4885NPSR1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.